These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32375399)

  • 1. Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.
    Ke C; Hou H; Li J; Su K; Huang C; Lin Y; Lu Z; Du Z; Tan W; Yuan Z
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32375399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular vesicle-mediated co-delivery of TRAIL and dinaciclib for targeted therapy of resistant tumors.
    Ke C; Hou H; Su K; Huang C; Yuan Q; Li S; Sun J; Lin Y; Wu C; Zhao Y; Yuan Z
    Biomater Sci; 2022 Mar; 10(6):1498-1514. PubMed ID: 35170591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy.
    Yuan Q; Su K; Li S; Long X; Liu L; Yang M; Yuan X; Sun J; Hu J; Li Q; Zhao Y; Yuan Z
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.
    Su K; Yuan Q; Hou H; Ke C; Huang C; Li S; Sun J; Yuan X; Lin Y; Chen Y; Xin H; Liang X; Du Z; Yuan Z
    J Mol Med (Berl); 2022 Apr; 100(4):629-643. PubMed ID: 35247069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective CDK9 knockdown sensitizes TRAIL response by suppression of antiapoptotic factors and NF-kappaB pathway.
    Yuan Q; Su K; Li S; Long X; Liu L; Sun J; Yuan X; Yang M; Tian R; Zhang W; Deng Z; Li Q; Ke C; He Y; Cheng C; Yuan J; Wen Z; Zhou W; Yuan Z
    Apoptosis; 2023 Aug; 28(7-8):1060-1075. PubMed ID: 37060507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy.
    Yuan Z; Kolluri KK; Gowers KH; Janes SM
    J Extracell Vesicles; 2017; 6(1):1265291. PubMed ID: 28326166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of CDK9 Inhibition by Dinaciclib in Combination with Apoptosis Modulating izTRAIL for the Treatment of Colorectal Cancer.
    Shen X; Kretz AL; Schneider S; Knippschild U; Henne-Bruns D; Kornmann M; Lemke J; Traub B
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
    Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
    Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
    Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
    Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).
    Hou H; Su K; Huang C; Yuan Q; Li S; Sun J; Lin Y; Du Z; Ke C; Yuan Z
    Adv Healthc Mater; 2021 Jun; 10(11):e2100030. PubMed ID: 33963815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
    Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
    Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.
    Hu C; Dadon T; Chenna V; Yabuuchi S; Bannerji R; Booher R; Strack P; Azad N; Nelkin BD; Maitra A
    Mol Cancer Ther; 2015 Jul; 14(7):1532-9. PubMed ID: 25931518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
    Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
    Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
    Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
    Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma.
    Huang C; He Y; Sun J; Yuan Q; Li S; Hou H; Su K; Ke C; Du Z; Yuan Z
    Acta Histochem; 2022 Feb; 124(2):151856. PubMed ID: 35077998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.
    Desai BM; Villanueva J; Nguyen TT; Lioni M; Xiao M; Kong J; Krepler C; Vultur A; Flaherty KT; Nathanson KL; Smalley KS; Herlyn M
    PLoS One; 2013; 8(3):e59588. PubMed ID: 23527225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
    Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
    Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
    Buzzetti M; Morlando S; Solomos D; Mehmood A; Cox AWI; Chiesa M; D'Alessandra Y; Garofalo M; Topham CH; Di Leva G
    Sci Rep; 2021 Mar; 11(1):5374. PubMed ID: 33686114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.